Title : The efficacy of pyrotinib-based therapy in lapatinib-resistant metastatic HER2-positive breast cancer.

Pub. Date : 2022 Jan

PMID : 35144424






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We investigated the efficacy of pyrotinib, a new irreversible tyrosine kinase inhibitor (TKI) targeting epidermal growth factor receptor, HER2, and HER4, in lapatinib-resistant HER2-positive MBC patients. Lapatinib erb-b2 receptor tyrosine kinase 2 Homo sapiens
2 METHODS: This is a retrospective observational study including lapatinib-resistant HER2-positive MBC patients who received pyrotinib-based treatment. Lapatinib erb-b2 receptor tyrosine kinase 2 Homo sapiens